Patent Application
20110144463
The present invention relates to a device, system and a method for measuring an analyte and in particular, to such a device, system and method in which the analyte from a bodily fluid is measured and/or monitored.
Diabetes is a very serious illness affecting millions of people. Many diabetic users are required to measure their glucose level 5-7 times a day to maintain proper blood glucose levels. Currently, individuals intermittently measure capillary blood glucose levels by extracting a few drops of blood using what are known as finger sticks. However, intermittent use is still based on a manual operation and handling of a lancet to prick the skin and the introduction of a “glucose test strip” to the drop of blood which comes out and performs a measurement of the blood glucose level. The procedure is manual, cumbersome and may be difficult to perform by young kids and the elderly. The procedure takes time and has to be performed carefully so as to ensure the accuracy of the measurement and to prevent the introducing of measurement errors due to operator. Additionally these devices require the operator to be awake in order to manipulate, work and/or activate the device.
Automatic glucose measurement can be performed by a new generation of continuous glucose monitors which allow individuals to continuously measure glucose levels. Some continuous glucose monitors include one or more sensors that are inserted or implanted into a blood vessel such as the vena cava. However, implanting a sensor into a blood vessel is a complicated process that currently requires a surgical procedure and involves potential severe adverse effects.
State of the art substance sensors are typically inserted into subcutaneous tissue. For example, the Guardian RT by Medtronic, the Navigator by Abbott and the STS by Dexcom measure glucose levels in interstitial tissue with such subcutaneous sensors. Such sensors comprise a selectively permeable membrane that allows glucose to flow through to an enzymatic assay that determines the relative glucose level.
Alternatively, the subcutaneous sensors include the microdialysis catheter substance sensors, such as for example Menarini GlucoDay for glucose measurement or the device of CMA microdialysis Microdialysis device Corp (USA) for measurement of several substances. In microdialysis the substance molecules diffuse into the catheter membrane and flow, optionally by use of a pump, to an external sensor, instead of inserting a sensor into the tissue, as is done in the subcutaneous biosensors.
Continuous Glucose Monitoring (CGM) sensors operate automatically to provide glucose readings after an initial calibration process and can also provide measurements during the time that the user is asleep. However, none of the Continuous Glucose Monitoring systems (CGM) are approved for primary or independent use by the regulatory authorities, such as the FDA and they are only approved for adjunctive use. The main reason for that is their relatively low accuracy, especially at low glucose levels when compared to glucose reading in samples taken from blood. Another limitation of the CGM is a change in their performance over time. Upon installation, the CGM is calibrated against measurement from blood samples from the finger using regular glucose meters. Based on these measurements and the sensor reading a calibration factor is calculated.
There is an unmet need for and it would be highly useful to have, an automatically and/or remotely operated modular analyte measuring device, system and a method for monitoring an analyte from a bodily fluid.
In at least some embodiments, the present invention overcomes the drawbacks of the background art by providing an automatically and/or remotely operated modular analyte measuring device, system and a method for monitoring an analyte from a bodily fluid. Preferably the device provides for measuring at least one or more analytes in an automatic predetermined manner while optionally and preferably determining an action to be performed based on such monitoring. Optionally the device according to the present invention may also be linked to a plurality of devices to form a closed loop system.
The term “bodily fluids” within the context of this application refers to any biological bodily fluid, preferably blood, but for example also including but not limited to interstitial fluid (ISF), saliva, urine or the like to measure an analyte diffused therein. A preferred and most favorable bodily fluid according to the preferred embodiment of the present invention is blood.
The term “analyte” within the context of this application preferably refers to glucose, but also refers to a measurable biological entity, peptide, fat, molecule, chemical, compound, solution, gas, carbohydrate or the like measured that may be detected from bodily fluid. Optionally and preferably the term analyte refers to glucose used for monitoring the insulin levels within the body. Optionally, the analyte may be cholesterol and or triglycerides for monitoring atherosclerosis.
The term “closed loop analyte monitoring” refers to a system and its components working together synergistically to provided control over analyte levels in a flowing bodily fluid, for example blood. For example, diabetics need to closely control their blood glucose levels. In order to achieve this control, a closed loop system is needed to maintain baseline blood glucose levels. Effectively, a closed loop monitoring system continuously measures blood glucose levels while providing an measured response in relation to any changes in the blood glucose levels, preferably by delivering the appropriate amount of insulin (or other substance in order to reduce blood glucose level) and possibly glucagon (or other substance in order to increase blood glucose level). Therefore a closed loop system within the context of diabetes comprises cycles of measuring and or inferring blood glucose levels and delivering relative amounts of insulin. Similar closed loop system for other measurable analytes for example cholesterol, hormone levels may be implemented with the device, system and method according to the present invention.
The term piercing element within the context of this application refers a mechanical device comprising a piercing and or cutting surface for example including but not limited to a lancet, blade, blade edge, sharp edge, needle, sharp point, scoring edge, tapered edge, cross shaped blade or the like for piercing the skin. Preferably, the skin is pierced to draw or release bodily fluids for analysis and/or measurement. Optionally a piercing element may comprise non mechanical instrumentation for piercing tissue for drawing a biological fluid for example including but not limited to laser, acoustic, piezoelectric, electrical, optical or the like technologies as is known and accepted in the art.
A preferred embodiment of the present invention provides for a method and device for automatic high reliability measurement of an analyte from a bodily fluid for example including but not limited to blood, urine, saliva, interstitial fluid or the like to measure glucose and/or other analyte levels.
Within the context of this application the term “analyte measuring medium” is interchangeably used with the terms, “analyte measuring strip”, “test strip”, finger sticks or the like to refer to the analyte measuring medium as are known and accepted in the art. In some embodiments specialized improvements of such analyte measuring mediums are disclosed, for example providing improved bodily fluid collection, and improved coagulation.
A preferable embodiment of the present invention provides for a wearable analyte measuring device that is adept to measuring an analyte, most preferably glucose, from a bodily fluid, most preferably blood, in seamless manner even during sleep. Most preferably the analyte measuring device may be coupled to the skin surface on an extremity for example along the arms and or legs. Optionally the analyte measuring device may be worn on an extremity for example including a finger tip, finger along its length, toe or the like.
An optional embodiment of the present invention for an analyte measuring device enables at least one and more preferably a plurality of measurements to be performed according to a predetermined number of measurements or controllable time frame, period, schedule and/or time interval. Optionally and preferably, such control is remotely provided by an external or remote triggering device.
Most preferably the analyte measuring device may be attached to the skin of a user while the result of the measurements may be communicated to at least one of the device itself, a local device, a remote device, or any combination thereof.
An optional embodiment of the present invention provides for an analyte measuring device and system wherein the measuring device may be remotely controlled. Optionally and preferably, remote control for example includes but is not limited to communicating a triggering command to initiate the device according to an optional embodiment of the present to undertake analyte measuring. Optionally, the results of such analyte measuring may be further communicated to at least one of the triggering source, a calling center, local display, a back office, a remote location or the like or any combination thereof.
A preferred embodiment of the present invention for an analyte measuring device preferably utilizes and comprise modified and device specific analyte measuring medium also referred to an analyte measuring elements for example including but not limited to test strips and/or finger sticks as known and accepted in the art.
A preferred embodiment of the present invention provides for an analyte monitoring device comprising at least two or more portions, wherein a first portion also referred as the reusable portion, is configured to be reusable allowing for repeated use while a second disposable portion is configured to be disposable most preferably for single time use. Most preferably disposable portion and reusable portion may be readily and securely associated or disassociated with one another. Optionally and preferably the secure association or disassociated is facilitated by the use of connectors that may be functionally manipulated to associate or disassociate a reusable portion and a disposable portion.
Most preferably, the disposable portion comprises disposable elements and parts that are most preferably adept for single or optionally limited use that are preferably associated with obtaining and/or sampling a bodily fluid, for example comprising a piercing element and test strip.
Most preferably the reusable portion is configured to provide at least one or more state of the art sensors or the like for measuring the sampled bodily fluid, for example including but not limited to amperemetric, acoustic, ultrasonic, optical, electromagnetic, infrared or the like systems or methods for measuring an analyte from a bodily fluid as is known and accepted in the art.
Optionally the reusable portion is configured to act as a power source to at least one or more of its optional components for example including but not limited to a controller, a motor for driving the disposable portion, an analog to digital converter, and a transponder to transmit data and receive commands from a remote unit and/or controller.
Optionally disposable portion and/or reusable portion may be adapted to accepted interchangeable faces for example including decorative faces.
Most preferably, device according to the present invention may be activated remotely via communication protocols known and accepted in the art for example including but not limited to contactless, RF, wireless, cellular, IR, Bluetooth or the like communication protocols.
Most preferably, device according to the present invention may further comprise a communication module providing for two way communication, for example both receiving data and sending data using communication protocols known and accepted in the art for example including but not limited to contact-less, RF, wireless, cellular, Bluetooth, IR or the like communication protocols.
Optionally, the analyte measuring device according to the present invention may comprise at least one or more tissue treatment elements for improving analyte measurement and/or analysis. Optionally, at least one or more tissue treatment element may optionally be used for example including but not limited to heating, mechanical massage, suction, electrical energy, ultrasound energy, optical energy, acoustic energy, vasodilatation drugs or the like.
Most preferably the analyte measuring device according to the present invention is realized as a modular analyte monitoring device that may be a member of a greater system for closed loop monitoring of an analyte sampled from a bodily fluid, most preferably blood. Optionally and preferably the continuous monitoring system comprises active control of the three primary monitoring facets including continuous monitoring, continuous response—optionally drug response—and continuous centralized processing and control. Optionally, device according to the present invention can directly interface, sync and link with a central controller device. Optionally, device according to the present invention can interface and interact with a plurality of devices within the closed loop system. Optionally, a plurality of modular device according to the present invention may interface with one another optionally using a communication port.
In some embodiments of the present invention there are more pairs of piercing element and analyte measurement element disposed within a single disposable unit, such that a plurality of measurements may be undertaken with the same analyte measuring device, for example located on the user's finger. For example, a multi use disposable analyte measuring device according to the present invention providing automatic predetermined or seamless measurement that may be particularly useful for infants, ambulatory applications, the disabled and or handicapped, or otherwise dependent user.
An optional embodiment of the present invention provides for a specialized analyte measuring element or medium comprising an analyte measurement channel along with at least one or more secondary functional areas, for example a blood coagulation element preferably to prevent excess bleeding at the piercing site. Optionally the functional elements may be disposed on the same surface or on opposite surfaces of the measuring element. Optionally blood coagulation element may take various forms for example including but not limited to a gauze pad, band aid, medicated pad with a coagulating agent, or the like elements for preventing excess blood loss and absorbing excess pooled blood.
In some embodiments the measuring unit may contain an optical sensor which can be used to measure if enough blood accumulated before advancing the strip to the blood pooling area. If a large enough blood sample exists on the skin the strip advances and performs the measurement. If the blood sample is not large enough the strip will not advance and other or additional methods will be employed to extract more and/or sufficient bodily fluid, most preferably blood before advancing the strip.
Optionally, a sensor may be utilized to determine if sufficient bodily fluid has been extracted. Optionally the sensor may be disposed either in the disposable portion or most preferably in the reusable portion. Optionally, the sensor may be composed of a light source at a wavelength which is absorbed strongly by hemoglobin and a light detector. The light source and light detector are aligned so that the light from the light source will be reflected from the skin piercing area into the light sensor. The skin is a good scattering surface, however, when that area is covered with enough blood the reflected signal will be strongly attenuated due to the hemoglobin absorption of light. When the light reading is below a certain level it indicates that a large enough blood sample is present on the skin.
Optionally, plurality of sensors with or without optical element can be used to measure the size and or volume of the extracted bodily fluid, such as blood. For example a tiny CMOS camera can be used to measure the size of the extracted blood drop.
In some embodiments of the present invention the analyte measuring strip might be advanced parallel to the skin and in contact with the skin to allow for the strip to collect blood scattered along the path of the advancing strip. The strip opening where the bodily fluid, most preferably blood, is absorbed into the strip is typically a 4 mm wide. The strip path can be long, for example as much as 5 mm. Hence the strip can collect blood sample from an area of about 20 mm̂2 (squared) which improves the blood collection efficiency and enhances the likelihood of collecting a sufficiently large sample for analyte measurement.
In an optional embodiment the piercing element and or analyte measuring device may be housed in a small hollow cylinder. Preferably the cylindrical housing may be composed of at single disposable unit. Optionally, the cylindrical housing may be composed of two or more portion having a first disposable portion and a second reusable portion. Optionally, the cylindrical housing may be composed of two disposable portions. Optionally, the cylindrical body may be disposed of expandable and/or rotatable elements providing for a housing comprising varying diameter. Optionally, the cylindrical body is elastic and or flexible.
In one preferred embodiment of the present invention the user may choose to have at least one and more preferably a plurality of measurements taken at one at a time (wherein each measurement is at a different time), and a different number of measurements taken at another time. Preferably the user can depict the number of measurements to be performed by adding or removing the number of disposable and/or reusable elements operated by the same remote controller. Preferably the controller can operate a plurality of measuring elements optionally based on predetermined and/or schedule, or based on a preset time interval, or based on the receipt of a triggering command to undertake measurement, or optionally by coordinating and monitoring the operational activity and/or status of a plurality of measuring elements simultaneously.
A further preferred embodiment of the present invention relates to systems and methods for measuring and monitoring an analyte in a bodily fluid. Optionally and preferably the system comprises at least one and more preferably a plurality of modular analyte measuring device as previously described and at least one or more controller. Optionally, the system according to the present invention comprises up to about 10 modular analyte measuring devices simultaneously in use with the controller.
Most preferably, the modular analyte measuring device comprises two portions a reusable portion and a disposable portion, as previously described. Most preferably, the disposable portion is configured for single use comprising a single use piercing element and analyte measuring medium. Preferably, reusable portion comprising a battery may be synced with the controller for recharging batteries. Most preferably, the reusable portion of the measuring device comprise communication module to provide for receiving and sending data relating to the analyte measurement. Communication protocols received from the controller for example includes but is not limited to triggering data, alarms, scheduling or the like instructions. Optionally and preferably, the reusable portion sends the measurement results to the controller, alarms, status data or the like information. Most preferably communication for either receiving or sending comprises at least one or more or a combination of communication protocols as is known and accepted in the art for example including but not limited to wired, physical, contactless, wireless, cellular, IR, RF, optical, Bluetooth or the like communication protocol.
Optionally and preferably, the controller may provide and/or display information regarding the analyte measuring device for example including, ready state, battery state, schedule timing, measurement status, measurement results, alarms or the like data. Most preferably ready state of the analyte measuring device is communicated once the reusable and disposable portions are securely associated and functional. Optionally the controller provides a unique identification label for each analyte measuring device it is associated and/or in communication with. Optionally and preferably the analyte measuring device may communicate to at least one or more controllers its state in relation to the user, for example indicating if the measuring device has been attached to a user and is in a ready to use format or similarly if the device is in the midst of obtaining a measurement.
Most preferably, the controller may be realized in at least one and optionally a plurality of associated units. Optionally the controller may be realized in the form of a remote unit and/or a proximal unit. Optionally and preferably the remote unit comprises communication protocols adept for long range wireless communication for example including but not limited to cellular, wireless, RF, IR, optical or the like long range communication protocols. Most preferably, the remote may be located at some distance from the analyte measuring device of the present invention while still maintaining communication channels enabling sending and/or receiving long range instructions.
Optionally and preferably the proximal unit comprises communication module adept for short range communication protocols for example including but not limited to Bluetooth, contactless RFID, IR, wired or the like communication protocols. Most preferably, the proximal controller unit may be located in the vicinity of the analyte measuring device according to a preferred embodiment of the present invention while still maintaining communication channels with at least one or both of the analyte measuring device and the remove controller unit.
Optionally, the remote and/or proximal units may be configured to securely associate or disassociate with one another preferably forming a single housing. Optionally, proximal and remote device may comprise controllable configurations for example master and slave, wherein most preferably the remote unit is the master. Optionally the controller, in either the proximal or remote configuration may be realized in the form of a PDA, cellular phone, mobile computer or the like processing tool. Optionally and preferably, the controller comprises, a display, for example an LCD screen, LED array, or the like. Optionally and preferably, the controller comprises user interface for setting and controlling its activity. Preferably, the controller comprises a speaker, user interface ports, charging port contactless port, sync port to associate with the reusable portion.
Most preferably alarm state is communicated to all modules comprising the system according to the present invention.
In one preferred embodiment of the present invention wherein the disposable element comprises a single lancet and a single test strip are housed together in a housing having one side that can be securely connected to the skin of a user, optionally human or animal. The housing is preferably further mechanically and electrically connected to a reusable element comprising a power source, controller, transponder and mechanical actuators. Optionally the combined measuring element comprising a reusable and disposable portion securely associate with one another to form an active measuring device also referred to as a measuring “button” having a size of about 10 mm×10 mm×5 mm. Most preferably, at least one or more of the measurement “buttons” may be attached to the user at the same time one time according to a predetermined number of measurements to be taken. Optionally and preferably a remote controller which can optionally take the form of a cellular phone may be used to control the measuring button's controller to trigger a single measurement at a time. Optionally and preferably the triggering command to perform a measurement may originate in plurality of sources for example including but not limited to be preset schedules, a preset specific time, a time intervals based on pervious measurements. Optionally a triggering command may optionally be received via mobile telephone communication for example including an SMS that is converted to a triggering command. Optionally the triggering command and/or mobile communication trigger may be received from an alternate cell phone and/or command center. Most preferably, each such measuring button performs only one measurement.
In yet another preferred embodiment the modular system comprising several “measuring buttons” such that one or more measuring buttons is placed on one body part (arm, leg) while one or more other measuring buttons are laced on a different body part (opposite arm, opposite leg).
In yet another preferred embodiment the system controller receive signal from a device that is placed on the user (on the skin or implanted) and in return initiates a measuring button to perform a measurement. The device that is placed on the skin or implantable can detect a physiological parameter or tissue analyte (like ISF glucose level, or eating activity).
An optional embodiment of the system may be configured to comprise at least one and more preferably a plurality of modular analyte measuring device as previously described, at least one controller as previously described and a treatment and/or drug delivery device.
Optionally and preferably a treatment and/or drug delivery device for example including but not limited to a drug delivery pump, a device for providing a treatment or medicament in light of a measured and/or sensed analyte levels. Most preferably, the drug delivery device is controlled by the controller wherein the dosage form, dosage amount or the like is determined and communicated to the drug delivery device.
Most preferably alarm state is communicated to all modules comprising the system according to the present invention.
An optional embodiment of the present application provides for a system utilizing continuous glucose sensor, for example including but not limited to an ISF Glucose Sensor (IGS), and Automatic Blood Glucose Sampling (ABGS) system as described with regard to some embodiments of the present invention or the like as is known in the art. Optionally an IGS and ABGS may be coupled to, a treatment device such as an insulin pump and controller.
Most preferably, the automatic glucose sensor continuously senses the glucose levels, from at least one or more preferably a plurality of sources for example including invasive measurements from a bodily fluid preferably ISF, but for example also including, blood, saliva, urine or the like, or form non-invasive measurements. Optionally, the ABGS is triggering by a change in the actual glucose levels or in the rate of change of the glucose levels, according to a schedule, or any combination thereof.
Optionally and preferably, the system according to the present embodiment communicates with a controller with at least one or more communication protocols as is known and accepted in the art for example including but not limited to contactless, wired, wireless, RF, IR, Bluetooth, cellular or the like. Optionally, the controller may be embodied in a processor, mobile phone, PDA, computer or the like.
Optionally and preferably, the system may further comprise a treatment indication and/or device for indicating or carrying out a treatment. For example including a pump and or infusion set may be utilized for administering and/or delivery a medicament or the like non-medicinal fluid, for example saline, glucose or the like. Optionally, treatment indication may be utilized to indicate to an appropriate course of action, for example self delivery of a medicament or food.
In some embodiments of the present invention, the ABGS according to the present invention can save at least one or more manual blood sampling currently needed to calibrate the IGS, sensors known in the art. Currently, the IGS technologies in the market require few calibrations with blood glucose readings. For instance, the Gaurdian RT requires calibration point 2 hours after the sensor insertion and later on every 12 hours. An IGS combined with ABGS can improve compliance comparing to the regular IGS and reduce the burden to the IGS user, by taking the blood glucose sampling automatically as required. In some embodiments, to get better accuracy of the IGS the calibration points may optionally and preferably be undertaken at specific conditions, such as at relatively stable glucose levels, such as <0.5 mg/dl/min glucose change, for period longer than 20 min, to minimize the difference between ISF and blood glucose levels, which become larger during larger variations of the glucose level. In this way, a better calibration accuracy of the IGS can be achieved and reduce the overall error of the IGS reading compared to blood glucose level. An optional good calibration point can be during the evening or at night when the user sleeps, after the postprandial glucose variation associated with the users food intake has passed. According to the present embodiment the ABGS can take the blood glucose measurement automatically, while the user sleeps.
Some embodiments of the present invention are particularly adept in dealing with important medical decision required due to low blood glucose levels that are in danger of reaching hypoglycemic levels a (blood glucose level <60 mg/dl) at a point where the user most preferably requires a quick increasing their blood glucose levels optionally by consuming carbohydrate or glucose rich foods or drinks having high glucose concentrations to elevate the blood glucose level to the normal glucose level (80-110 mg/dl). Currently, IGS devices fail to provide good enough alarm for hypoglycemia because of their accuracy limitations, especially at low glucose level. An optional embodiment of the present invention provides for an additional automatic blood sample at instances of low glucose levels to overcome the IGS inaccuracy problem therein providing an accurate reading of the blood glucose at such critical times. Accordingly an optional embodiment of the present invention can act as a support to improve the hypoglycemic alarm most preferably to level of no false alarms therein preferably facilitating any medical decision that may optionally be derived at, such as glucose or carbohydrates consumption.
Another optional embodiments of the present invention provides for improved ISG calibration during a user's physical activity preferably by triggering an analyte measurement according to the present invention during such physical activity. It is known that activity level may alter the reading of the ISG sensor and destroy the calibration. The ABGS can be triggered and used to improve ISG sensor reading therein restoring calibration. In some embodiment the level of activity may be determined based on a gyro-meter and/or accelerometer placed on the ABGS or on the ISG sensor to trigger the activity of the analyte measuring device (ABGS) of the present invention.
In some embodiments the initiation of the ABGS is based on the subject skin temperature. It is known that the skin and body temperature may alter the reading of the ISG sensor and destroy the calibration. The ABGS can be triggered to improve ISG sensor reading and restore calibration. In some embodiments the skin temperature may be determined by a temperature sensor placed on ISG sensor.
In some embodiments the ABGS is initiated when the IGS reading drops below a certain level, such as 70 mg/dl. In this case some automatic blood glucose measurements may be initiated even though the real glucose level is higher, which means that the user is not in a hypoglycemic state however this goes undetected with an IGS readings alone. An optional embodiment of the present invention the IGS sensor may be recalibrated based on the blood glucose levels detected by the ABGS of the present invention to ensure accurate IGS tracking the glucose level. In some embodiments, if the IGS reading further decrease another automatic blood glucose measurement can be initiated and the process can repeat until the glucose level goes up to the normal level. Optionally, the threshold for initiating an automatic blood glucose measurement can be set to determine the trigger level.
In some embodiments the ABGS is initiated when the IGS reading drops below a certain level, such as 80 mg/dl accompanied glucose decrease rate above a certain level, for example above 2 mg/dl/min. The combination of rapid glucose decrease and relatively low glucose level will trigger the ABGS to avoid un-safe state which may result from the combination of inaccuracies due to, rapid glucose change and relatively low glucose level. An algorithm can be used to determine if a certain state (combination of glucose level and glucose change rate) triggering of the ABGS to improve accuracy. Rapid glucose decrease will require initiation of the ABGS at higher glucose level. For example rapid glucose change above 3 mg/dl/min will induce initiation of the ABGS at glucose level such as 90 mg/dl.
In some embodiments the ABGS is initiated when the IGS reading drops or increased too rapidly, such as in a rate larger than 2 mg/dl/min, where the accuracy of IGS readings is known to be too low. In this case the IGS readings can be recalibrated according to the ABGS reading and the IGS can keep tracking the glucose level and/or alert the user as required.
In some embodiments the ABGS is initiated in certain time points after the IGS reading starts to increase at a rate higher than a certain rate, such as 1 mg/dl/min, and indicating that the user had a meal or consumed some carbohydrates. Currently, most diabetic users have large postprandial glucose excursions because of the large difference between the desired effect of the insulin and the actual effect which depends on many parameters currently not available to the user, such as the temporal insulin resistance and the gastric absorption time constant of the carbohydrates. Such large postprandial glucose excursions can be reduced by measuring the postprandial glucose level after certain periods from the meal start and fixing the insulin dose accordingly. However, the accuracy of the IGS readings is not accurate and reliable enough for calculation of the required insulin dose adjustment. By adding an ABGS sampling the problem of the IGS accuracy can be solved. For instance the glucose level can be measured 1 hour or 2 hours after the meal starts and the insulin bolus starts its action. Preferably in this case an algorithm that may take into account also additional parameters, such as consumed carbohydrates, the infused insulin history and the user sensitivity to insulin could optionally and preferably provide the adjustment to the insulin dose in order to reduce the postprandial glucose excursions.
In case of using rapid acting insulin, such as the insulin analogues or even faster acting insulin such as the ViaJect or using a drug delivery device that improves the insulin absorption, such as described in U.S. application Ser. No. 11/812,230 which is hereby incorporated by reference as if fully set forth herein, or intradermal delivery, the insulin clearance from the tissue is faster then in the regular insulin. In those cases it may be more feasible to take additional glucose measurement and adjust the insulin dose to regulate the blood glucose level, since the insulin residual concentration in the tissue is very small and it is easier to calculate the additional dose that is required for regulating the glucose level.
In some embodiments the ABGS is initiated when the IGS reading drops below a certain level, such as 70 mg/dl at night. In this case the automatic blood glucose measurements may be initiated to get a more accurate and reliable glucose reading that if confirm that the glucose level getting low it may initiate an immediate action to correct that. In some embodiments the device may communicate with the insulin pump and stop or decrease or recommend decreasing the basal insulin delivery. In some embodiments the device may alert the user that the glucose level is getting low and wake him up as described at several configurations at the present application. In some embodiments, such as in young diabetic users, the device may alert a third party, such as the user's parents and wake them up, so they can give the diabetic user the required treatment. In some embodiments a combination of the above described actions can be performed. The advantage of using the combined sensor over the current situation is in reducing false alarms and improving the acceptance of the device by the user. Reports suggests that some of the subjects do not use the IGS system at nights due to the high level of false alarms.
In some embodiments the ABGS is initiated at a certain time of the day or night in anticipation of glucose changes for example around dawn where changes in glucose level are expected due to the release of certain hormones in the middle of the night which work around the action of insulin. This may lead to increase in glucose level in the early morning. To improve accuracy of the sensor at those times where large change in glucose may occur a pre-determined ABGS initiation may be applied. Also the point in time which the ABGS is initiated may be calibrated to suit individual glucose profile either during the day or during the night. Using this predetermined initiation an increased accuracy of glucose measurement may be achieved. Another phenomena which may cause temporal change in glucose is Rebound hyperglycemia which may cause a low glucose level around 3 A.M. A pre-determined initiation of the ABGS will ensure accurate glucose measurement at this point in time. The exact time of initiation may vary between individual and hence may be set individually
In some embodiments, the insulin dose or rate may be determined by a processing unit that preferably obtains the glucose level readings and most preferably derives the required insulin dose or rate that most preferably may then be infused. In some embodiments this information may be optionally and preferably displayed to a user preferably allowing the user to confirm the reading prior to infusion of the insulin. In an optional embodiments the user confirmation is not required, wherein the glucose readings are most preferably sufficiently accurate and reliable to support automatic dosing of insulin or a closed loop control system to regulate the glucose level in the body. Currently the IGS readings which are available for such closed loop system are not accurate and reliable enough for supporting that. The combination of the IGS with ABGS as described by the present application can provide the required accuracy and reliability that can safely enough support such a closed loop system. In some embodiments of the present invention a closed loop for controlling blood glucose level can be constructed by combining an insulin pump, a processing unit, an ISG sensor along with ABGS. Based on the accurate glucose measurement of the combined glucose sensor, the processing unit can calculate the required amount of insulin whether as a bolus or change to the basal rate and inject the required insulin using the insulin pump. Alternatively the processing unit will calculate the required insulin and will wait for user authorization before injection by the pump.
In some embodiments, the automatic blood glucose sampling can be done by automatically pricking the user skin in a blood rich area such as the forearm and then a applying the small blood droplet to a glucose sensor, such as a finger stick that measure the glucose level. In some embodiments the lancet using for the skin pricking is disposable and used once. In some embodiments a magazine or cartridge of lancets are used for single pricking each. In some embodiments the glucose sensor, such as finger stick used for measuring the glucose level is disposable and used once. In some embodiments a magazine or cartridge of glucose sensors is used for single glucose tests in the same device. Devices like described above are known in the art, such as described in U.S. Pat. No. 7,041,068 and many others, all of which are hereby incorporated by reference as if fully set forth herein. The ABGS can be disposed on the forearm or the arm leg or other body parts with relatively high perfusion.
In some embodiments the ABGS includes a method for tissue stimulation to improve local blood perfusion and get a more accurate blood glucose reading. An example for local tissue stimulation that improves the local blood perfusion is heating to in intermediate temperature, such as in the range of 35-42° C., which is known in the art to improve local blood perfusion. Other types of tissue stimulations for improving local blood perfusion are optical radiation, mechanical vibrations, suction, massaging, acoustic stimulation (such as in the ultrasonic range), electrical stimulation, microwave or radiofrequency radiation, etc.
In some embodiments the suggested combination of the IGS with ABGS is used for conducting an insulin bolus estimation calculation. In some embodiments, the combination of the IGS with ABGS device communicates a bolus amount resulting from the bolus estimation calculation to the insulin pump, which delivers a bolus of insulin to a user based on the communication from the combination of the IGS with ABGS device. The insulin infusion device delivers the insulin automatically after receiving the communication from the combination of the IGS with ABGS device.
In some embodiments the ABGS and IGS may be on the same unit and at the same body location where the IGS system measures the glucose level in the ISF fluid and the ABGS measures the glucose in the blood, such as in the dermal layer which is rich in blood vessels.
In some embodiments, the combination of the IGS with ABGS device comprises a processor and an IGS sensor coupled to the processor through wired or wireless communication channel. The processor may include a display and user interface options such as buttons. The blood glucose sensor that measures the sampled blood droplets is coupled to the same processor unit through wired or wireless communication channel or to a separate processor unit which can communicate by wires or wirelessly to the IGS processor. In some embodiments both the IGS and the ABGS include processors which communicate by wires or wirelessly to a separate process to exchange information. In some embodiments both the IGS and the ABGS include processors which communicate by wires or wirelessly to each other to exchange information. In some embodiments both the IGS and the ABGS include processors which communicate by wires or wirelessly to each other to exchange information and the display unit and user interface are placed on one of the units.
In some embodiments, the combination of the IGS with ABGS device comprises a processor and an IGS sensor coupled to the processor through wired or wireless communication channel and blood glucose sensor that measures the sampled blood droplets coupled to the processor unit through wired or wireless communication channel, both combined to provide an estimation of the concentration of the glucose in the user's blood. In some embodiments a communication circuit is coupled to the processor. The processor is adapted to calculate an amount of the insulin or fluid to be infused into the user's body based upon the sensors output signal, and to cause the monitoring device communication circuit to transmit a set of data indicative of the amount of the insulin to be infused.
In some embodiments, an indicator is coupled to the combination of the IGS with ABGS device processor and adapted to provide a notification of the following events: the measuring of the output signal produced by the sensor, the calculating of the amount of the fluid, and the transmitting of the set of data by the first communication circuit.
In some embodiments the insulin infusion device comprises a processor and a drive mechanism coupled to the processor and adapted to infuse the fluid into the user's body. A communication circuit is coupled to the processor and adapted to receive the set of data from the monitoring device communication circuit. The processor is adapted to cause the drive mechanism to automatically infuse the fluid into the user in accordance with the set of data.
In some embodiments, the combination of the IGS with ABGS device communication circuit is a transmitter or a transceiver, and the infusion device communication circuit is a receiver or a transceiver.
In some embodiments, the combination of the IGS with ABGS device further comprises a user input device for inputting commands. The monitoring device communication circuit transmits the first set of data in response to a command from the input device.
In some embodiments, the combination of the IGS with ABGS device processor is further adapted to determine according to a specific algorithm, such as described before, the optimal periods for initiating the automatic blood glucose sampling to recalibrate the IGS reading. In some embodiments, the combination of the IGS with ABGS device processor is further adapted to determine according to a specific algorithm, such as described before, the optimal periods for initiating the automatic blood glucose sampling to accurately and reliably estimate the amount of insulin bolus to be infused. In some embodiments, the combination of the IGS with ABGS device processor is further adapted to determine according to a specific algorithm, such as described before, to update the insulin basal rate if required, such as in case of hypoglycemia event.
In some embodiments, the combination of the IGS with ABGS device further comprises an indicator coupled to the monitoring device processor and adapted to provide a display of the amount of the fluid and a user input device for inputting commands. The combination of the IGS with ABGS device processor is further adapted to cause the monitoring device communication circuit to transmit the first set of data in response to a first command from the input device.
It should be noted that the methods and devices described in the present application for blood glucose level estimation can be used for accurately monitor the level of other substances in the blood or the human body. The methods described for controlling an insulin infusion device can be used similarly to control infusion of other substances required to control or regulate the glucose level in the body or control or regulate other processes or substances in the human body.
Unless otherwise defined the various embodiment of the present invention may be provided to an end user in a plurality of formats, platforms, and may be outputted to at least one of a computer readable memory, a computer display device, a printout, a computer on a network or a user.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The materials, methods, and examples provided herein are illustrative only and not intended to be limiting. Implementation of the method and system of the present invention involves performing or completing certain selected tasks or steps manually, automatically, or a combination thereof. Moreover, according to actual instrumentation and equipment of preferred embodiments of the method and system of the present invention, several selected steps could be implemented by hardware or by software on any operating system of any firmware or a combination thereof. For example, as hardware, selected steps of the invention could be implemented as a chip or a circuit. As software, selected steps of the invention could be implemented as a plurality of software instructions being executed by a computer using any suitable operating system. In any case, selected steps of the method and system of the invention could be described as being performed by a data processor, such as a computing platform for executing a plurality of instructions.
It should be noted that optionally any device featuring a data processor and/or the ability to execute one or more instructions may be described as a computer, including but not limited to a PC (personal computer), a server, a minicomputer, a cellular telephone, a smart phone, a PDA (personal data assistant), a pager. Any two or more of such devices in communication with each other, and/or any computer in communication with any other computer, may optionally comprise a “computer network”.
The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in order to provide what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.
In the drawings:
The present invention, in at least some embodiments, is for an automatic and/or remotely controlled and operated modular analyte measuring device, system and a method for monitoring an analyte from a bodily fluid. Preferably the device provides for measuring at least one or more analytes in an automatic predetermined manner while optionally and preferably inferring an action based on such monitoring. Optionally the device according to the present invention may also be linked to a plurality of devices to form a closed loop system.
The principles and operation of the present invention may be better understood with reference to the drawings and the accompanying description.
Most preferably, device 300 may be securely attached to or coupled to any external skin surfaces 306 that would allow piercing element 330 to extract or draw sufficient bodily fluid, for example including but not limited to blood and/or interstitial tissue, from an underlying tissue 308 for analyte measurement and analysis. Optionally device 300 may be adhered, attached or otherwise coupled to an external skin surface for example including but not limited to hip, back, abdomen, arm, leg or the like skin surface. Preferably device 300 is preferably be attached to body locations used as primary or alternate sites for capillary glucose measurements such as the arm or leg.
Optionally and preferably, device 300 may be provided with an adhesive layer 302 to facilitate the coupling of device 300 to skin surface 306 underlying tissue 308.
Optionally, device 300 may comprise at least one or more tissue treatment element 302 for improving analyte measurement and/or analysis. Optionally, at least one or more tissue treatment element may optionally be use for example including but not limited to electrical energy, ultrasound energy, optical energy, acoustic energy, vasodilatation drugs or the like. For example, a heating pad may be disposed on the lower surface of device 300 between adhesive layer 304 and bottom surface of housing 301.
Optionally housing 301 may be adapted to accepted interchangeable faces for example including a decorative faces.
Most preferably, device 300 may be activated remotely via communication protocols known and accepted in the art for example including but not limited to contactless, RF, wireless, cellular, IR or the like communication protocols.
Most preferably, device 300 may be activated remotely via communication protocols known and accepted in the art for example including but not limited to contactless, RF, wireless, cellular, IR or the like communication protocols.
Most preferably, device 300 may further comprise a communication module (not shown) providing for two way communication, for example both receiving data and sending data using communication protocols known and accepted in the art for example including but not limited to contact-less, RF, wireless, cellular, IR or the like communication protocols.
Optionally and preferably, analyte measuring device 300 may comprise a single device that may optionally be associated with disposable or interchangeable analyte measuring mediums 332 while its functional parts maintained in a single housing. Optionally, disposable portion may comprise piercing element 330. Optionally disposable portion may be composed of at least one of analyte measuring medium 332 and/or piercing element 330.
Most preferably, analyte monitoring device 300 comprises at least two or more portions functionally separable portions, wherein a first portion is a reusable portion (not shown) that is configured to be reusable allowing for repeated use while a second portion (not shown) configured to be disposable optionally for a limited time and/or single use. Optionally, disposable portion and reusable portion may be readily and securely associated or disassociated with one another. Optionally and preferably the secure association or disassociated is facilitated by the use of connectors that may be functionally manipulated to associate or disassociate reusable portion with disposable portion.
Optionally and preferably, device 300 is realized as a modular analyte monitoring device that may be a member of a greater system for closed loop monitoring of an analyte sampled from a bodily fluid. Optionally and preferably the continuous monitoring system comprises active control of the three primary monitoring facets including continuous monitoring, continuous response—optionally drug response—and continuous centralized processing and control. Optionally, device 300 can directly interface, sync and link with a central controller device. Optionally, device 300 can interface and interact with a plurality of devices within the closed loop system. Optionally, a plurality of modular devices 300 may interface with one another optionally using a communication port.
Most preferably, piercing element 330 protrudes and pierces the underlying skin layer 306 through opening 310. Most preferably, opening 310 allows for bodily fluid to flow from the underlying tissue 308 into opening 310 wherein it may be reacted with at least on or more analytes measuring element 332.
Optionally the directional displacement of measuring element 332 by movement module 350 may be rotational providing for up to 360 degree movement form an initial position within housing 301. Optionally rotational motion may be from about 20 degree movements to 180 degree displacement form an initial position within housing 301. In general, rotational motion fits more to analyte measuring element 332 which has side opening for sampling of bodily fluid.
Optionally directional displacement of measuring element 332 by movement module 350 may optionally be planar providing for displacement in the horizontal plane and or vertical plane. Optionally, directional displacement of measuring element 332 by movement module 350 may optionally comprise both planar and rotational movements. Optionally, directional displacement of measuring element 332 by movement module 350 may optionally be arched with respect to lower surface of housing 301. Optionally directional displacement of measuring element 332 by movement module 350 may to displace measuring element 332 from an initial position outside of housing 301 for example a position defined by opening 312 as described in
An optional embodiment of analyte measuring device 300 of
Most preferably, analyte monitoring device 800 comprises at least two or more portions wherein a first portion 820, also referred as reusable portion, is configured to be reusable allowing for repeated use while a second portion 810 is configured to be disposable optionally for limited and/or single time use. Most preferably disposable portion 810 and reusable portion 820 may be readily and securely associated or disassociated with one another. Optionally and preferably the secure association or disassociated is facilitated by the use of connectors that may be functionally manipulated to associate or disassociate reusable portion 820 with disposable portion 810.
Most preferably, disposable portion comprises disposable elements and parts that are adept for single or limited use that are preferably associated with obtaining and/or sampling a bodily fluid. Most preferably reusable portion 820 is configured to provide at least one or more state of the art sensors or the like for measuring the sampled bodily fluid, for example including but not limited to amperemetric, acoustic, ultrasonic, optical, electromagnetic, infrared or the like systems or methods for measuring an analyte from a bodily fluid as is known and accepted in the art.
Most preferably, disposable portion 810 comprises: housing 801, a recess 806 for receiving and connecting with reusable portion 820, at least one or more piercing elements 830, clamp 802 for coupling to reusable portion 820, an analyte analysis element 832, electrical contacts 816 and 818 for analyte analysis element, association electrical contact connectors 838 and 836, two wings 812 and 814 preferably disposed on either side of recess 806 preferably for extracting bodily fluid for analysis by squeezing the pierced tissue; a heating element 834, and coated with biocompatible adhesive layer coating 816 on its bottom side covered with laminate 818.
Most preferably, the reusable portion 820 comprises housing 801, piston 822, spring 824, at least two or more electrical contact couplers 846 and 848, electrical contacts 826 and 828, at least one or more coupling recess 842 and controller 840.
Optionally and preferably, device 800 may be provided with an adhesive layer 816 to facilitate the coupling of device 800 to skin surface where measurement is to be undertaken.
Optionally housing 801 and/or housing 801 may be adapted to accepted interchangeable faces for example including decorative faces.
Most preferably, device 800 may be activated remotely via communication protocols known and accepted in the art for example including but not limited to contactless, RF, wireless, cellular, IR or the like communication technology and/or protocols.
Most preferably, device 800 may further comprise a communication module (not shown) providing for two way communication, for example both receiving data and sending data using communication protocols known and accepted in the art for example including but not limited to contact-less, RF, wireless, cellular, IR or the like communication protocols.
Optionally, device 800 may comprise at least one or more tissue treatment elements for improving analyte measurement and/or analysis. Optionally, at least one or more tissue treatment element may optionally be used for example including but not limited to heating, massaging, mechanical stimulation, electrical energy, ultrasound energy, optical energy, acoustic energy, vasodilatation drugs or the like.
Optionally and preferably, device 800 is realized as a modular analyte monitoring device that may be a member of a greater system for closed loop monitoring of an analyte sampled from a bodily fluid. Optionally and preferably the continuous monitoring system comprises active control of the three primary monitoring facets including continuous monitoring, continuous response—optionally drug response—and continuous centralized processing and control. Optionally, device 800 can directly interface, sync and link with a central controller device. Optionally, device 800 can interface and interact with a plurality of devices within the closed loop system. Optionally, a plurality of modular devices 800 may interface with one another optionally using a communication port.
Most preferably lancet 831 may be provided in optional different shapes for example including but not limited to lancet, blade, blade edge, sharp edge, needle, sharp point, scoring edge, tapered edge, cross shaped blade or the like depending on where the measurement is to be taken and the blood volume required for the analyte measurement by an analyte measuring element. For example, lancet 831 is most preferably provided in the shape of a scoring blade-like edge when measurement is performed at an alternative piercing site, for example including but not limited to a leg and/or arm. A blade like lancet 831 preferably increases the likelihood of producing a piercing that provides sufficient blood volume to allow for blood glucose measurement with an analyte measuring element, most preferably a finger stick, when used at an alternate measuring site for example a leg and/or arm, or the like measuring site, with a minimum discomfort to the user. For example when measuring from the finger tip lancet is most preferably provided in the form of a sharp pointed edge or needle.
Measurement is undertaken as described above and known in the art. Optionally and preferably reusable portion 820 and disposable portion 810 are separated wherein a disposable portion 810 is disposed of while a new one is attached to the same reusable portion 820.
In an optional embodiment after piercing, the controller initiates a predetermined time lag, for example about 7 seconds, before moving the analyte measuring element toward the released blood droplet. Preferably such a time lag provides sufficient time for bloodletting and pooling at the piercing site to accumulate a sufficient blood volume. Preferably and optionally, a time lag may be coordinated with the type of lancet used with the piercing element. For example, using a blade like lancet 831 combined delay of 7 sec before measuring the blood sample provides increased likelihood for extracting a large enough blood sample from the measuring site, most preferably an alternate site such as a limb, arm and/or leg. For example, this optional combination could produce a blood sample of about 0.6 micro liters of blood, which is a preferred for volume for an analyte measuring element, for example glucose test strips. Optionally, other analyte measuring elements prefer a blood sample size volume in the range of about 0.3 to 1 micro liter, where the 0.3 micro liter test strips are the most preferably for measuring the blood glucose level at alternate sites, such as limbs, arm or leg. In some embodiments to further increase the likelihood of obtaining a sufficiently large blood sample a specific type of treatment element may be applied to the measurement are before and/or after piercing. For example, massaging the piercing site preferably using wings 812 and 814 or optionally heating the tissue, preferably using heating element 834 in and around the piercing site, to preferably increase the local blood perfusion. Optionally other optional treatment elements may be used and coordinated with the time delay before measuring the blood sample with analyte measuring element, such as the glucose test strip.
Most preferably a time lag may be adapted to allow sufficient blood volume to accumulate preferably according to at least one or more parameters, for example including but not limited to measurement location, lancet type, local blood perfusion, treatment element and the employed analyte measuring element or an analyte measuring sensor.
In some embodiment of the present invention a specific blood volume sensor, for example an optical sensing element may be provided to verify that large enough blood sample has been extracted. Optionally, such a blood volume sensor may be utilized by the controller to coordinate movement of the analyte measuring element toward the blood sample most preferably to perform the analyte measurement with increased likelihood of obtaining a successful and accurate measurement of the blood glucose level. Optionally a blood glucose volume sensor may be incorporated into analyte measuring element, such as the glucose test strip. Optionally a blood volume sensor may be disposed within the housing of the analyte measuring device of the present invention, for example within the disposable portion and/or reusable portion.
Most preferably, analyte monitoring device 100 comprises at least two or more portions wherein a first portion 120, also referred as reusable portion, is configured to be reusable allowing for repeated use while a second disposable portion 110 is configured to be disposable optionally for a limited and/or single time use. Most preferably disposable portion 110 and reusable portion 120 may be readily and securely associated or disassociated with one another. Optionally and preferably the secure association or disassociated is facilitated by the use of connectors that may be functionally manipulated to associate or disassociate reusable portion 120 with disposable portion 110.
Most preferably, disposable portion comprises disposable elements and parts that are adept for single or limited use that are preferably associated with obtaining and/or sampling a bodily fluid. Most preferably reusable portion 120 is configured to provide at least one or more state of the art sensors or the like for measuring the sampled bodily fluid, for example including but not limited to amperemetric, acoustic, ultrasonic, optical, electromagnetic, infrared or the like systems or methods for measuring an analyte from a bodily fluid as is known and accepted in the art.
Most preferably, disposable portion 110 comprises: housing 101, at least one or more connectors 107, at least one or more piercing elements 130, rotational element 103 and extremities adaptor element 105.
Most preferably, the reusable portion 120 comprises housing 102, rotating element 126, at least one or more analytes monitoring and measuring elements 146 and 148, display indicator 122 and electronic module 124, which comprises processing unit, power source and communication element.
Optionally housing 102 and/or housing 101 may be adapted to accepted interchangeable faces for example including decorative faces.
Most preferably, device 100 may be activated remotely via communication protocols known and accepted in the art for example including but not limited to contactless, RF, wireless, cellular, IR or the like communication protocols.
Most preferably, device 100 may further comprise a communication module (124) providing for two way communication, for example both receiving data and sending data using communication protocols known and accepted in the art for example including but not limited to contact-less, RF, wireless, cellular, IR or the like communication protocols.
Optionally, device 100 may comprise at least one or more tissue treatment elements for improving analyte measurement and/or analysis. Optionally, at least one or more tissue treatment element may optionally be used for example including but not limited to heating, mechanical stimulation, electrical energy, ultrasound energy, optical energy, acoustic energy, vasodilatation drugs or the like.
Optionally and preferably, device 100 is realized as a modular analyte monitoring device that may be a member of a greater system for closed loop monitoring of an analyte sampled from a bodily fluid. Optionally and preferably the continuous monitoring system comprises active control of the three primary monitoring facets including continuous monitoring, continuous response—optionally drug response—and continuous centralized processing and control. Optionally, device 100 can directly interface, sync and link with a central controller device. Optionally, device 100 can interface and interact with a plurality of devices within the closed loop system. Optionally, a plurality of modular devices 100 may interface with one another optionally using a communication port.
Optionally and preferably, rotating element 126 provides an interface between reusable portion 120 and disposable portion 110. Preferably rotating element 126 functions to trigger the corresponding rotation elements 103 and piercing element 130 (not shown here) disposed in disposable portion 110.
Most preferably, the rotating interface provided by rotating element 126 allows for the rotation of disposable portion 110 relative to the reusable portion. Optionally rotating element may be activated manually, remotely or automatically. Optionally rotating element may be activated according to a schedule. Optionally, rotating element 126 may be activated remotely via communication protocols known and accepted in the art for example including but not limited to wireless, cellular, IR or the like communication protocols.
Optionally and preferably extremities adaptor element 105 comprises finger adaptor 150 (not shown) and at least one or more preferably a plurality of fine tuning extremities adjusting elements 152. Most preferably extremities adjusting elements 152 provide for a comfortable and secure fit for analyte measuring device 100 over an extremity for example including a finger or toe.
Preferably, rotating element 126 rotates, for example at about 100 degrees, counterclockwise around the extremity associated thereto preferably a finger and/or toe. Preferably, the rotational angle depends on the configuration and may be adapted to a user or a particular configuration. Optionally ration may be set to be up to 360 degrees; optionally and preferably up to about 180 degrees. Most preferably rotational motion is powered by a circular spring (not shown) disposed inside reusable portion 120. Optionally and preferably, when rotating element 126 is triggered it brings about the rotation of rotating ring 112 and its rounded beam 116 comprised in disposable rotational element 103. Most preferably, rounded beam 116 is displaced counterclockwise triggering the bend of piercing element 130 via flexible beam 114, preferably causing it to pierce the skin of the extremity attached thereto. Then rotating ring 112 continues to rotate an additional 10 degrees to deactivate therein releasing piercing element 130 and flexible beam 114 while moving analyte measuring medium 132, most preferably a test strip, toward the piercing site on the extremity surface. Body fluid, for example including but not limited to blood, is expelled from the piercing site then comes into contact with analyte measuring medium 132 and/or capillary channel 134. Preferably and optionally capillary channel 134 is defined by a recess or otherwise embedded within analyte testing medium 132. Optionally and preferably, bodily fluid is the displaced within the capillary channel 134 optionally and preferably by capillary action, wherein an analyte for example including but not limited to glucose is measured.
Optionally, ring shaped device 200 may comprise a single device that may optionally be associated with disposable analyte measuring mediums while its functional parts maintained in a single housing.
Optionally, device 200 may comprise at least one or more tissue treatment element (not shown) for improving analyte measurement and/or analysis. Optionally, at least one or more tissue treatment element may optionally be use for example including but not limited to heating, mechanical stimulation, electrical energy, ultrasound energy, optical energy, acoustic energy, vasodilatation drugs or the like.
Optionally housing 202 and/or housing 201 may be adapted to accepted interchangeable faces for example including decorative faces.
Most preferably, device 200 may be activated remotely via communication protocols known and accepted in the art for example including but not limited to contactless, RF, wireless, cellular, IR or the like communication protocols.
Most preferably, device 200 may further comprise a communication module (not shown) providing for two way communication, for example both receiving data and sending data using communication protocols known and accepted in the art for example including but not limited to contact-less, RF, wireless, cellular, IR or the like communication protocols.
Optionally and preferably, device 200 is realized as a modular analyte monitoring device that may be a member of a greater system for closed loop monitoring of an analyte sampled from a bodily fluid. Optionally and preferably the continuous monitoring system comprises active control of the three primary monitoring facets including continuous monitoring, continuous response—optionally drug response—and continuous centralized processing and control. Optionally, device 200 can directly interface, sync and link with a central controller device. Optionally, device 200 can interface and interact with a plurality of devices within the closed loop system. Optionally, a plurality of modular devices 200 may interface with one another optionally using a communication port.
Reusable portion 220 depicted in
An optional embodiment of analyte measuring device 300 of
Piercing element 702 is driven trough the center of the cylinder body 701 with spring 704 to piercing the skin surface (not shown) and than it retracts to return to its steady state position. The blood is then pooled at pooling area 708 at the bottom of hollow cylinder 701. Optionally, after a predetermined time or optionally after sufficient bodily fluid is pooled into pooling area 708 an analyte measuring element 710 is advanced into the cylinder trough a side opening 712, optionally with a movement module 350 described in detail in
Optionally, the method described in
Optionally and preferably the method described in
Optionally and preferably the method described in
Optionally and preferably the method described in
In stage 1000 the disposable and reusable portions of the analyte measuring device according to the present invention are securely associated with one another to render the analyte measuring device functional and ready for use. Next, in stage 1002 the analyte measuring device is attached or otherwise coupled to a user of a measuring site to await a triggering signal preferably from a controller, optionally from at least one of the remote controller unit and/or a proximal controller unit. Optionally, the site and manner in which it is associate depends on the device utilized according to an optional embodiment of the present invention. Next in stage 1004 a triggering signal is received from a controller, optionally a controller may indicate to a user to manually trigger or initiate measurement. Next in stage 1006 optionally a treatment element is activated to increase blood perfusion at the targeted piercing site. Optionally, the treatment may include mechanical massage, heat, ultrasound, delivery of energy, delivery of electrical energy, drug delivery, or the like treatment to improve blood circulation in and around the targeted piercing site. Next in stage 1008, the piercing element is put into action to pierce the underlying tissue releasing a bodily fluid most preferably blood. Optionally and preferably the timing is controller mediated optionally by implementing a predetermined and controllable delay from the triggering signal of stage 1002 or time of the day or optionally with a second triggering signal for piercing activation communicated by at least one controller to the reusable portion of the analyte measuring device of the present invention. Next in stage, 1010 a sensor preferably with the reusable portion and optionally in the disposable portion determines if sufficient blood volume has been released. Optionally and preferably blood volume determination is mediated with communication with the controller or optionally by local controls within the reusable portion of the measuring device according to the present invention. Optionally if it is determined that there is an insufficient amount of blood volume for measurement to take place, optionally and preferably the controller initiates an appropriate treatment protocol to increase blood volume, as described in stage 1006. Optionally, instead of measuring the amount of extracted blood at this stage, a predetermined delay between piercing and measurement, for example 7 seconds is set in order to have high likelihood that enough blood for accurate measurement was pooled. Optionally if it is determined that there is sufficient blood volume to allow for a meaningful measurement and analysis the controller signals or triggers the activity of the movement module preferably as described in movement module 350 of
The analyte measuring devices according to the present invention described above in
An optional embodiment of the present invention comprises a modular system for providing closed loop control of an analyte monitoring system, for example including but not limited to glucose, cholesterol, triglycerides or the like analyte measurable from a bodily fluid most preferably blood and or interstitial fluid.
A preferable embodiment of the present invention is the analyte monitoring system of the present invention that is specifically adapted for monitoring the analyte level, most preferably glucose, during sleep. More specifically as applied for the younger individuals where diabetes management is difficult particularly at night.
Most preferably each of the components of the closed loop system are in continuously communication using communication protocols as is known and accepted in the art.
Optionally and preferably, controller 1120 preferably comprises a display 11120, user interface 1114, speakers 1116, communication module 1118, as well as at least one or more sync port modules 1115. Preferably, sync port module allows to physically interact and/or associate with other system devices for example including but not limited to optional analyte monitor devices as described in
Optionally and preferably, user interface 1114 optionally in the form of a keyboard, keypad, and/or touch screen allows a user to interface directly with the device and the various components, for example, setting timing of drug delivery or of measurements, schedules or the like.
Optionally system 1110 may be realized with one or more controllers. Optionally, a first controller may be configured to be a primary controller 1110 also referred to as a remote controller located at a distance from user 1101. Optionally and preferably as second controller unit 1120 and proximally located near user 1101, also referred to as proximal controller 1120 is similarly used to communicate with and coordinate between the plurality of measuring devices 100, 300, 1104 and 200 defined and used within the system. Most preferably proximal controller 1120 is close to user 1101 and is in communication with using near range communication protocols for example including but not limited to wireless, Bluetooth, contactless RFID or the like. Optionally and preferably proximal controller 1120 comprises long range communication ability for example including but not limited to cellular, wireless, optical or the like long range communication protocols as is known and accepted in the art. Optionally and preferably, proximal controller 1120 may comprise the same components and interface as remote controller 1110. Optionally, proximal controller 1120 and remote controller 1110 may be associated with one another. Optionally, proximal controller 1120 and remote controller 1110 may be interchangeable with one another.
Optionally, controller 1120 may be realized as an identical unit to controller 1110 however comprising a master/slave controller hierarchy. Optionally, controller 1120 may be realized as a small unit comprising only essential components for example including but not limited to communication module (not shown) and display.
In stage 1300 the controllers are set and loaded with the appropriate data for example including the number of analyte measuring devices used, most preferably one per each measurement required in a given time period. For example during nigh sleep if three measurements are required then three analyte measuring device will be utilized, where in stage 1300 the timing of each will be set. Next in stage 1302 the analyte measuring device of choice is placed in the measuring area, most preferably extremities such as the arms, legs, fingers and or toes. The device configuration used depends on the locations. Next the controller and the measuring devices communicate and begin to countdown until the time for measurement occurs. Optionally, the trigger for measurement may be an auxiliary unit, for example a continuous glucose monitoring device, such as 1104 shown in
While the invention has been described with respect to a limited number of embodiments, it will be appreciated that many variations, modifications and other applications of the invention may be made.
The present application claims priority to U.S. Provisional Patent Application No. 61/067,424 entitled “Method and Device for Substance Measurement” filed on Feb. 27, 2008, and incorporates its disclosure herein by reference in its entirety, U.S. Provisional Patent Application No. 61/067,423 entitled “Analyte Monitoring Device and Method” filed on Feb. 27, 2008, and incorporates its disclosure herein by reference in its entirety, U.S. Provisional Patent Application No. 61/054,180 entitled “Analyte Monitoring Device and Method” filed on May 19, 2008, and incorporates its disclosure herein by reference in its entirety, U.S. Provisional Patent Application No. 61/058,938 entitled “Analyte Monitoring Device and Method” filed on Jun. 5, 2008, and incorporates its disclosure herein by reference in its entirety, U.S. Provisional Patent Application No. 61/059,773 entitled “Analyte Monitoring Device and Method” filed on Jun. 8, 2008, and incorporates its disclosure herein by reference in its entirety, U.S. Provisional Patent Application No. 61/094,915 entitled “Analyte Monitoring Device and Method” filed on Sep. 7, 2008, and incorporates its disclosure herein by reference in its entirety and U.S. Provisional Patent Application No. 61/094,916 entitled “Analyte Monitoring Device and Method” filed on Sep. 7, 2008, and incorporates its disclosure herein by reference in its entirety.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/IL09/00221 | 2/26/2009 | WO | 00 | 10/19/2010 |
| Number | Date | Country | |
|---|---|---|---|
| 61067424 | Feb 2008 | US | |
| 61067423 | Feb 2008 | US | |
| 61054180 | May 2008 | US | |
| 61058938 | Jun 2008 | US | |
| 61059773 | Jun 2008 | US | |
| 61094915 | Sep 2008 | US | |
| 61094916 | Sep 2008 | US |
